Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
AbelZeta’s FDA-cleared registrational Phase II trial will evaluate the investigational dual-target CAR-T therapy C-CAR168 in patients with refractory lupus nephritis. Representative image.
Pharma & Biotech

Can AbelZeta turn a tiny lupus dataset into a registrational CAR-T breakthrough?

AbelZeta's FDA-cleared Phase II C-CAR168 trial tests whether dual-target CAR-T can deliver durable renal responses in refractory lupus nephritis.

Read More
Laboratory research illustrates Decoy Therapeutics’ investigation of D-MAV antiviral candidates after reporting early in vitro activity against Ebola Zaire virus. Representative image.
Pharma & Biotech

A coronavirus antiviral candidate hit Ebola in the lab. How far can Decoy Therapeutics take it?

Decoy Therapeutics reports early Ebola Zaire activity, but potency data, animal validation and funding will determine the D-MAV program.

Read More
Representative image: Laboratory blood samples illustrate Freenome’s SimpleScreen CRC FDA approval as Abbott Laboratories $ABT prepares to launch the blood-based colorectal cancer screening test in the United States.
Pharma & Biotech

FDA approves Freenome SimpleScreen CRC blood test as Abbott prepares US launch

FDA approves Freenome’s SimpleScreen CRC blood test as Abbott plans a fall launch. See its benefits, limits and colonoscopy requirement.

Read More
Liberate Bio’s appointment of Steven H. Bernstein as chief medical officer comes as the biotechnology company advances its LIB820 in vivo CAR-M cell-programming candidate toward planned clinical evaluation. Representative image.
Pharma & Biotech

Liberate Bio has primate data and a new CMO. Can its in vivo CAR-M platform make the clinical leap?

Liberate Bio appoints Steven Bernstein as CMO as LIB820 advances toward a first human study in systemic sclerosis and in vivo CAR-M validation.

Read More
An inhaled pulmonary arterial hypertension therapy advances toward United States Food and Drug Administration review as Gossamer Bio regains worldwide seralutinib rights and prepares its planned NDA submission. Representative image.
Pharma & Biotech

Gossamer Bio reacquires worldwide seralutinib rights from Chiesi ahead of NDA submission

Gossamer Bio plans a September seralutinib NDA after FDA talks as Chiesi rights, cash pressure and Phase 3 risk reshape the case.

Read More
Yarrow Bioscience’s merger with VYNE Therapeutics and the start of Phase 2 dosing for investigational YB-101 place Graves’ disease and thyroid eye disease research at the centre of the newly listed biotechnology company’s strategy. Representative image.
Pharma & Biotech

Yarrow Bioscience closes VYNE Therapeutics merger as YB-101 enters Phase 2 trial in Graves’ disease

Yarrow Bioscience starts Phase 2 dosing of YB-101 after its VYNE merger, testing a targeted approach to Graves’ disease and thyroid eye disease.

Read More
Teladoc Health Canada’s Accreditation Canada Primer Award highlights the growing focus on quality, safety and governance standards across virtual and hybrid healthcare delivery. Representative image.
Pharma & Biotech

Teladoc Health Canada just gained a powerful quality credential, but what will healthcare buyers demand next?

Teladoc Health Canada earns Accreditation Canada’s Primer Award, strengthening its quality credentials as virtual and hybrid care expands.

Read More
A courtroom gavel symbolises the $4 million Biohaven and Yale University trade secret verdict involving Avilar Therapeutics, RA Capital Management and the MODA protein degradation platform. Representative image.
Pharma & Biotech

What Biohaven’s Avilar trade secret verdict means for the MoDE protein degradation platform

Biohaven and Yale won a $4 million MODA trade secret verdict, strengthening the platform narrative as BHV-1300 enters Phase 3.

Read More
Kelun-Biotech’s investigational dual-payload antibody-drug conjugate SKB565 advances toward Phase 1/2 clinical testing for advanced solid tumors following a China clinical trial notice. Representative image.
Pharma & Biotech

SKB565 clinical trial: Why Kelun-Biotech’s first dual-payload ADC matters

Kelun-Biotech’s SKB565 gains China clinical trial clearance, moving its first dual-payload ADC toward a Phase 1/2 solid-tumor study.

Read More
IDEAYA Biosciences is advancing IDE892 into monotherapy expansion as the investigational PRMT5 inhibitor targets MTAP-deleted lung and pancreatic cancers. Representative image.
Pharma & Biotech

What IDEAYA Biosciences’ IDE892 expansion means for MTAP-deleted cancers

IDEAYA advances IDE892 into expansion after reaching target exposure, but clinical response and safety data remain the decisive test.

Read More